Abilify (generic: aripiprazole) is an antipsychotic medication used to treat the symptoms of schizophrenia, bipolar disorder, mania, and other depressive disorders in adults. Abilify is made by Bristol-Myers Squibb, and was approved by the U.S. Food & Drug Administration (FDA) in 2002.

Unfortunately, Abilify has been linked to the increased risk of uncontrollable impulse control disorders like compulsive gambling, shopping, eating, and sex addiction/hypersexuality.

If you have suffered from addictive gambling behavior after taking Abilify, YOU ARE NOT ALONE.

Almost 3,000 Abilify Gambling Lawsuits Filed

As of September 2019, there are nearly 3,000 lawsuits filed against the manufacturers of Abilify, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co. Our lawyers are currently representing a number of Abilify patients who have been financially devastated by this dangerous drug.

Free Abilify Lawsuit Review
If you or somebody you know has suffered from gambling losses after taking Abilify, you may be entitled to financial compensation by filing an Abilify lawsuit.

Lawsuits on Abilify and gambling seek recovery for:

  • Damaged reputation
  • Emotional distress
  • Financial losses
  • Gambling losses
  • Medical fees
  • Punitive damages

Our class action lawyers offer a free review of your potential case. Please click the button below to submit your information online or call us directly by dialing (866) 588-0600.

Start My Free Case Review

Abilify Settlements

It is important to understand that Bristol-Myers Squibb and Otsuka Pharmaceutical Co. has already agreed to a confidential settlement. This settlement covered certain individuals who were part of litigation in some Federal and State courts.

Abilify Settlement

Abilify Side Effects

Our lawyers are representing people who were prescribed Abilify and subsequently suffered financial loss due to uncontrollable gambling.

According to Drugs.com, frequent Abilify side effects include dizziness, drowsiness, lethargy, sedated state, urinary incontinence, and salivation. Visit their website to learn more.

Additional Information: Abilify Prescribing Information

Abilify Gambling Warning

Screenshot of Abilify label warning of “Pathological Gambling and Other Compulsive Behaviors.

Is There an Abilify Class Action?

At this time, no class action lawsuit has been filed in the Abilify litigation. However, our lawyers are currently filing individual lawsuits for people who have suffered from compulsive behavior side effects such as Abilify induced gambling.

Contact us today to learn more about your legal rights. If we determine that you have a valid claim, you may be eligible to receive settlement money for your losses.

Abilify Lawsuits Claiming Gambling Addiction

Side effects of Abilify caused a Minnesota woman to rack up a large amount of debt as a result of compulsive gambling, according to a recent lawsuit. Plaintiff Denise Miley alleges that she began suffering uncontrollable urges to gamble shortly after she began taking Abilify in September 2014. Her need to gamble went away after quitting the drug in February 2015, but by that time she had already accumulated in excess of $75,000 in debt, according to the complaint.

Abilify Gambling Lawsuits Centralized in Florida Federal Court

Multidistrict litigation (MDL No. 2734) has been created in the Northern District of Florida for federal lawsuits alleging pathological gambling side effects from Abilify. There are currently at least 22 such complaints pending in 12 different jurisdictions, in addition to another 20 actions in 14 districts the judges were recently notified about, according to the Transfer Order (PDF).

Bristol-Myers Requests Florida as Venue for Abilify Gambling MDL

Bristol-Myers has filed a motion with the U.S. Judicial Panel on Multidistrict Litigation (JPML) to send dozens of lawsuits alleging compulsive gambling side effects from Abilify to federal court in Pensacola, Florida. The drugmaker contends that the Northern District of Florida makes sense since 13 Abilify lawsuits have already been consolidated in New Jersey state court and that other plaintiffs have consented to the proposed jurisdiction.

Abilify Labeling Updated to Include Gambling, Compulsive Behaviors Warning

The U.S. Food & Drug Administration (FDA) has revised the labeling of Abilify to include a warning (PDF) for “pathological gambling and other compulsive behaviors.” The warning notes that patients may not recognize such behaviors as abnormal, counsels physicians to ask about such behaviors, and recommends discontinuation or dose reduction if these behaviors appear.

It is interesting to note that the labels on European and Canadian versions of Abilify warned about the risk of “pathological gambling,” but the manufacturers chose not to warn American patients about the side effects until 2016.

Massachusetts Woman Alleges Compulsive Behaviors from Abilify

Rikki Carlson of Fall River, Massachusetts, has filed a personal injury lawsuit against Bristol-Myers Squibb and Otsuka Pharmaceutical, alleging that her use of Abilify caused her to have compulsive behaviors including gambling, shopping and binge eating. Carlson says she started taking Abilify in or around December 2010 and began compulsively gambling and shopping shortly thereafter; these behaviors ceased promptly after she quit the drug in March 2016, according to the complaint.

Public Citizen Demands ‘Black Box Warning’ on Antipsychotic Meds

The watchdog group Public Citizen sent a petition (PDF) to the FDA requesting ‘black box warnings’ to dopamine agonist antipsychotic drugs regarding an increased risk for compulsive behaviors such as gambling, sexual obsessions, and shopping. According to the letter, more than 80 studies link these medications to compulsive behaviors. Although the petition did not focus specifically on Abilify, but it did acknowledge data indicating that it was related to the same side effects.

Abilify Gambling Lawsuits May Be Headed for Consolidation

More than 2 dozen lawsuits alleging that Abilify caused gambling addiction and other compulsive behaviors could soon be formed into multidistrict litigation (MDL), according to Reuters. There are currently at least 26 such complaints pending in federal courts around the country, in addition to 13 cases in New Jersey state court that have already been consolidated. The Motion for Transfer requests that the U.S. Judicial Panel on Multidistrict Litigation (JPML) expedite the matter and schedule oral arguments for its next hearing session, which is set for July 28 in Seattle. The proposed consolidation is In Re: Abilify Compulsive Behavior Products Liability Litigation – MDL No. 2734.

FDA Updates Abilify Warning Label to Include Compulsive Behavior Warning – Gambling Addiction

May 3, 2016 – FDA is warning that use of Abilify or other aripiprazole-containing antipsychotic drugs may increase compulsive or uncontrollable urges to gamble, binge eat, shop and have sex. The agency warned that the impulsive behaviors, though rare, may cause harm to the patient or others if not identified. FDA is requiring the addition of new warnings to include these behaviors in the drug labels and Medication Guides for all aripiprazole-containing medications.

Again, it is interesting to note that the labels on European and Canadian versions of Abilify warned about the risk of “pathological gambling,” but the manufacturers chose not to warn American patients about the side effects until 2016.

class action lawyer

Do I Have an Abilify Gambling Lawsuit? Contact a Lawyer Today.

The Class Action & Product Liability Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Abilify lawsuits. We are handling individual litigation nationwide and currently handling Abilify gambling cases in all 50 states.

Again, if you or somebody you know has suffered from gambling losses after taking Abilify, you may be entitled to financial compensation by filing an Abilify lawsuit.

Our lawyers offer a free review of your potential case. Please use the form below to contact us today.

FREE Confidential Case Evaluation

To contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.